RVT 201
Alternative Names: RVT-201Latest Information Update: 28 Oct 2019
At a glance
- Originator Roivant Sciences
- Class
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Atopic-dermatitis in Unknown
- 02 Sep 2016 Phase-I clinical trials in Atopic dermatitis before September 2016 (Roivant Sciences pipeline, September 2016)
- 01 Sep 2016 Preclinical trials in Atopic dermatitis in Bermuda before September 2016 (Roivant Sciences pipeline, September 2016)